BlackRock, Inc. 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | MONTE ROSA THERAPEUTICS INC CO GLUE | BlackRock, Inc. BLK | 3,840,165 6.300% | 1,468,185 (+61.90%) | Filing |
| 2024-02-14 11:22 am Sale | 2023-12-31 | 13G | MONTE ROSA THERAPEUTICS INC CO GLUE | BlackRock, Inc. BLK | 2,371,980 4.700% | -1,226,556 (-34.08%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | MONTE ROSA THERAPEUTICS INC CO GLUE | BlackRock, Inc. BLK | 3,598,536 7.400% | 2,006,738 (+126.07%) | Filing |
| 2022-02-09 5:22 pm Sale | 2022-01-31 | 13G | MONTE ROSA THERAPEUTICS INC CO GLUE | BlackRock, Inc. BLK | 1,591,798 3.400% | -761,966 (-32.37%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | MONTE ROSA THERAPEUTICS INC CO GLUE | BlackRock, Inc. BLK | 2,353,764 5.100% | 2,353,764 (New Position) | Filing |